Stop TB Partnership

Partnership objectives

  1. By 2015, reduce the global burden of TB disease (deaths and prevalence) by 50%, relative to 1990 levels.
  2. By 2050, achieve the global incidence of TB at less than 1 per million population for elimination of TB as a global public health problem.

When people cannot or do not take all their treatment TB bacilli become resistant to them and multidrug-resistant TB (MDR-TB) can develop. MDR-TB takes longer to treat and can only be cured with second-line drugs- more expensive with more side-effects. When people cannot or do not take all their treatment TB bacilli become resistant to them and multidrug-resistant TB (MDR-TB) can develop. MDR-TB takes longer to treat and can only be cured with second-line drugs- more expensive with more side-effects. Copyright WHO/Jean Chung

Partnership objectives Description of partnership activities and how they address needs and challenges

The Stop TB Partnership was established in 2000 to realize the goal of eliminating tuberculosis (TB) as a public health problem. It comprises a network of more than 500 international, governmental, nongovernmental and private sector organizations and individuals with an interest in working together to achieve this goal. The Partnership is a global movement to accelerate social and political action to stop the spread of TB around the world. A number of IFPMA members, including AstraZeneca, Bayer, GlaxoSmithKline, Lilly, Novartis, and Pfizer are currently partners of the Stop TB Partnership and/or actively contribute to its aims and programs.

The partnership develops advocacy and resource mobilization strategies in support of these priorities, and coordinates and 'brokers' resource flows. In addition, there are six Working Groups that contribute significantly to the achievement of partnership aims: DOTS Expansion Working Group; TB-HIV Working Group; Stop TB Working Group on MDR-TB; Working Group on New TB Drugs, Working Group on New TB Diagnostics and Working Group on New TB Vaccines.

The Stop TB Partnership Private Sector Constituency is the community of businesses with a recognized role or interest in TB control. The Private Sector has been represented on the Coordinating Board of the Global Stop TB Partnership since 2004, following a proposal by the World Economic Forum.

The Global Drug Facility, run by the Stop TB Partnership, is expanding access to medicines for DOTS scale up; in just 5 years it has committed over 7 million TB treatments. Projects managing MDR-TB can apply through the Green Light Committee (GLC) for access to quality MDR-TB medicines at reduced prices - in some cases by as much as 99%. The Committee is operated by WHO and the Stop TB Partnership. Lilly has a program to make two critical medicines for treatment of drug-resistant strains available in developing countries and will supply 1.4 million vials of capreomycin at concessionary prices to the GLC in 2009. Novartis is donating 500,000 fixed dose combinations to all adult patients in Tanzania through the Global Drug Facility during 2005-2012. To improve access and treatment compliance, the Novartis Foundation for Sustainable Development together with the Tanzanian Ministry of Health and Social Welfare introduced a patient-centered treatment approach, offering TB patients the choice whether to take the treatment at a health facility or at home, observed by a family member (DOT- directly observed treatment). Early 2016, Otsuka committed to enhancing access to delamanid for treating multidrug-resistant TB (MDR-TB) in low- and middle-income countries. The company will moreover support communities with education, training, technical assistance, and TB advocacy activities.


"I want Zero TB deaths in my lifetime"

Partnership information

Company(ies) AstraZeneca , Bayer , Eli Lilly and Company , GlaxoSmithKline , Johnson & Johnson , Novartis , Otsuka

Partner(s) Medecins Sans Frontieres (MSF) / Doctors without Borders, Red Cross, Stop TB Partnership

Type of Partner(s) Multilaterals, NGOs

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR), Tuberculosis

Program Type(s) Availability of Treatment - Differential Pricing, Availability of Treatment - Product Donations, Research & Development - Development of Treatments, Research & Development - Pediatric R&D

Targeted Population(s) Children, Marginalised / Indigenous People, Men, Patients in needs of treatment, People with low income, Women, Youth

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 22

Country(ies) Afghanistan, Bangladesh, Brazil, Cambodia, China, Democratic Republic of the Congo, Ethiopia, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, Philippines, Russia, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zimbabwe

Start Date 2000

More information Stop TB

Completed date 2013